Cancers on the Rise: Changing Concepts Trends in … Concepts Thyroid Pathology Sylvia L. Asa, M.D.,...

Dr. S. L. Asa Thyroid Pathology

Changing Concepts Changing Concepts Thyroid PathologyThyroid Pathology

Sylvia L. Asa, M.D., Ph.D.

Professor Department of Laboratory Medicine and Pathobiology

University of TorontoPathologist-in-Chief

Medical Director, Laboratory Medicine ProgramUniversity Health Network

Toronto General Hospital/ Toronto Western Hospital/Princess Margaret Hospital

Cancers on the Rise:Cancers on the Rise:Trends in SEER Incidence Rates Trends in SEER Incidence Rates by Primary Cancer Site 1992by Primary Cancer Site 1992--20022002

Underlying rates are per 100,000 and age-adjusted to the 2000 U.S. standard population* The APC is significantly different from zero (p<0.5). Graph excludes data for cancers on the decline.Source: National Cancer Institute. Seer Cancer Statistics Review 1975-2002.

*

*

*

All Races, Males

3.1

3.0

2.5

0 1 2 3 4 5

Thyroid

Liver& IBD

Melanoma ofthe Skin

Annual Percentage Change Over Time

*

*

*

All Races, Females

3.3

2.3

0 1 2 3 4 5

Thyroid

Liver& IBD

Melanoma ofthe Skin

Annual Percentage Change Over Time

4.8

Thyroid Cancer Mortality Thyroid Cancer Mortality in the United Statesin the United States

• It is estimated that 1,530 americans (880 women, 650 men) will die of thyroid cancer in 2007

• Thyroid cancer is the fastest-rising cause of cancer-related death in men

• ¾ of annual deaths are from well-differentiated thyroid cancers

1. American Cancer Society, Cancer Facts and Figures. 20072. National Cancer Institute, SEER Cancer Statistics Review, 1975-20023. Robbins et al. Adv Intern Med. 2001; 46: 277-2944. Hundahl et al. Cancer. 1998; 83: 2638-2648

Estimated Thyroid Estimated Thyroid CancerCancer--Related DeathsRelated Deaths

Anaplastic11%

Papillary50%

Follicular27%

Hurthle12%

Thyroid Histology:Thyroid Histology:The The ““Gold StandardGold Standard””

Hyperplasia vs NeoplasiaBenign vs MalignantIndolent vs Aggressive Malignancy

• Observer-dependent• Inconsistent• Lack scientific criteriaLloyd RV et al, Am J Surg Pathol 2004;28:1336-40Elsheikh T et al, Am J Clin Pathol 2008;130:736-44

Follicular Adenoma orFollicular Adenoma orPapillary Carcinoma?Papillary Carcinoma?

The Answer:The Answer:5 Years Later5 Years Later

• Do we overcall many to catch this one?

• Do we undercall many and miss this one?

• Do we find scientific markers to predict behavior?


Sporadic Nodular GoiterSporadic Nodular Goiter• Multinodular

“colloid” goiter• Occasionally

associated with hyperthyroidism » “Plummer’s

disease”• Etiology and

pathogenesis NOT understood

Clonality Studies ofClonality Studies ofSporadic Nodular GoiterSporadic Nodular Goiter

• Dominant nodules often monoclonal• Nodules may show LOH or aberrant methylation• Multiple nodules from a single goiter exhibit

activation of the same allele

?Diagnostic criteriaApel et al; Diagn. Mol. Pathol. 1995; 42:113-121

Follicular Adenomas with Follicular Adenomas with Papillary ArchitecturePapillary Architecture

• “Papillary adenomas”• Monoclonal benign neoplasms• Activating mutations of

TSH-receptor or Gsα• Plummer’s disease

(Lyons et al, Science 249:635, 1990;van Sande et al,

J Clin Endocrinol Metab 80:2577, 1995)

Follicular Adenoma & Carcinoma

• Encapsulated expansile growth

• Malignant by capsular or vascular invasion

• Hematogenous spread

Definitions: Capsular InvasionDefinitions: Capsular Invasion1. Nests, cords or cells in

capsule 2. Islands in capsule

associated with perpendicular rupture of collagen

3. In capsule beyond bulk of lesion

4. Total thickness into adjacent parenchyma

?? Artefactual trapping?? postFNA

What If There Is NO What If There Is NO Tumor Capsule?Tumor Capsule?• Capsular invasion

cannot be evaluated• Invasion must be

assessed as infiltration into

surrounding parenchyma, perineural or vascular involvement


Classification ofClassification ofFollicular CarcinomaFollicular Carcinoma• Minimally invasive carcinoma

up to 100% 10 year survival

• Widely invasive carcinoma25-45% 10 year survival

• Angioinvasive carcinomacontroversial

Vascular Invasion by Vascular Invasion by Endocrine NeoplasmsEndocrine Neoplasms

1. Tumor cells bulging into an endothelial-lined lumen

2. Intravascular tumor nests covered with endothelium

3. Tumor casts within vessel lumen

4. Thrombus adherent to invasive tumor

? artificial implantation X

Identification of Vascular Invasionby Follicular Neoplasms• Rigid criteria

predict high likelihood of metastasis EVEN in differentiated thyroid carcinomaMete and Asa, submitted

Papillary Carcinoma:Papillary Carcinoma:A Cytologic DiagnosisA Cytologic Diagnosis

• Architecture irrelevant» Papillary, Follicular, Mixed, Solid , Cystic» Diffuse sclerosis variant is hard to recognize

• Invasion not a criterion» Encapsulated variant

• Nuclear features predict behavior

Papillary Carcinoma

• Often multifocal• Locally infiltrative• Lymphatic spread

Follicular Variant of Papillary Ca

• Encapsulatedexpansile growth

• Malignant bynuclear features

• Oftenmultifocal

• Lymphaticspread


Cytologic Features ofCytologic Features ofPapillary CarcinomaPapillary Carcinoma1. Enlarged, overlapping nuclei

2. Pale vacuolated nucleoplasm with peripheral margination of chromatin

3. Irregular nuclear membrane

4. Nuclear grooves

5. Nuclear pseudoinclusions

Emerin Identifies Nuclear Features

What Can Molecular Pathology What Can Molecular Pathology Teach Us Teach Us

About Thyroid Cancer?About Thyroid Cancer?

Markers of Thyroid Malignancy:Markers of Thyroid Malignancy:HBMEHBME--11

• Monoclonal antibody• Unknown epitope• Unknown significance• Identified in 60% of

thyroid malignancies, not in normal or benign lesions

Markers of Thyroid Malignancy:Markers of Thyroid Malignancy:GalectinGalectin--33• 31kD β-galactoside-

binding lectin• High percentage of

malignant thyroid tumors, not in normal or benign lesions

Markers of Papillary Carcinoma: Markers of Papillary Carcinoma: CK19CK19

• one of many keratins• identified diffusely in 60%

of papillary carcinomas• also seen in reactive

nontumorous thyroid

Raphael et al, Mod Pathol. 1995;8(8):870-2


TSH signaling MAPK signaling

ERK

MEK

BRAF

Gsa

cAMP

RAS

TSH receptor

Transcription

ERKP

PKA

CREB

CREBP

Adenylylcyclase RTK

TSH GF

P

P

Cell differentiation

Cell proliferation

P

Point mutations or rearrangement in thyroid cancers

Point mutation in hyperfunctioning

adenomas

GTP

P

Follicular cell

Mechanisms of Thyroid TumorigenesisMechanisms of Thyroid Tumorigenesis

Kondo, Ezzat and Asa, Nature Reviews Cancer 2006

Follicular Adenomas with Follicular Adenomas with Papillary ArchitecturePapillary Architecture

• “Papillary adenomas”• Monoclonal benign neoplasms• Activating mutations of

TSH-receptor or Gsα• Plummer’s disease

Lyons et al, Science 249:635, 1990;van Sande et al,

J Clin Endocrinol Metab 80:2577, 1995

BRAF MutationsBRAF Mutations

• Most common genetic event in thyroid cancer

• Diagnostic marker of PTC• Genotype-phenotype correlations

» BRAFV600E in classical variant PTC (common)» BRAFK601E in FVPTC (rare)» VK600-1E deletion (BRAFVK600-1E) in solid variant

(single case)• Prognostic significance controversial

RetRet/PTC Rearrangements/PTC Rearrangements• Chromosomal rearrangement

involving chromosome 10 ret• Fusion of the ret tyrosine kinase

to :CCDC6 (H4) = ret/PTC1*R1α = ret/PTC2NcoA4 (ele) = ret/PTC3*» Chromosome 10 inversions

most commonAt least 15 identified to date

RetRet/PTC Rearrangements/PTC RearrangementsEC TKTM

CCDC6 (H4)

R1α

NcoA4 (ele 1)

These rearrangements result in cytoplasmic protein;antibodies against ret identify the C terminus that is conserved

ret/PTC-1

ret/PTC-2

ret/PTC-3

ret

Richardson et al: Cancer Res 2009;69:4861-4869.

Different promoters drive transcript levels that modulate oncogenicity of RET/PTC oncoproteins.

Methods of Methods of RetRet/PTC Analysis/PTC Analysis• DNA

» PCR analysis difficult due to variable break-point sites leading to heterogeneous tumor profiles

• RNA» RT-PCR for ret/PTC mRNA is the “gold standard”» Variability of expression; not “all or none”

• Protein» Immunohistochemistry using antisera to C terminus

• FISH» Not widely available but promising

Rhoden et al, JCEM 2006


RAS Mutations Characterize RAS Mutations Characterize Follicular LesionsFollicular Lesions

• Follicular Variant PTC• Follicular Adenoma• Follicular Carcinoma• Poorly Differentiated Carcinoma

Pax 8Pax 8--PPARPPARγγ 1 Fusion Oncogene1 Fusion Oncogene

• Identified in angioinvasive follicular caKroll TG et al, Science, 2000; 289:135

• Diagnostically applicable by FISH and IHC for PPARγ• Also found in PTC Nikiforova et al: AJSP2002;26(8):1016-23

• Reduced membrane stain for β-Catenin correlates with dedifferentiation

• Nuclear translocation due to exon 3 mutation in 25% of insular carcinomas and 65% of anaplastic carcinomas

Garcia-Rostan et al, Am J Pathol 2001;158:987

CTNNB1 Mutations are Found in CTNNB1 Mutations are Found in Poorly Differentiated (Insular) Poorly Differentiated (Insular) Thyroid CarcinomaThyroid Carcinoma

PIK3CA Mutations Predict PIK3CA Mutations Predict Aggressive BehaviorAggressive Behavior

• Identified in anaplastic carcinoma» Garcia-Rostan et al, Cancer Res 2005;65:10199-207» Wang et al, JCEM 2007;92:2387-90

• Accompanies other mutations in aggressive papillary carcinoma and metastases» Costa et al, Clin Endocrinol 2008;68:618-34» Ricate-Filho et al, Cancer Res 2009;69:4885-93

p53 Alterations in Thyroid Carcinomap53 Alterations in Thyroid Carcinoma

Mutations are common inAnaplastic carcinoma ↓

Immunolocalization correlates with extent of disease, extrathyroidal involvement, recurrence and poor outcome in differentiated carcinoma

Hosal et al, Endocr Pathol 1997, 8:21-28

Molecular Studies:Molecular Studies:Progression in Thyroid CancerProgression in Thyroid Cancer

ThyroidFollicular

Cell

FollicularAdenoma

FunctioningFollicularAdenoma

FollicularCarcinoma

PapillaryCarcinoma

Tall Cell Papillary

Carcinoma

Insular Carcinoma

GsTSH-R

BRAFRET/PTCTRK

p53

β-cateninPIK3CA

PPARγ

MetastaticPapillary

Carcinoma

HyperplasiaAnaplasticCarcinoma

β-cateninPIK3CARas


What is the Clinical Significance of What is the Clinical Significance of Papillary Microcarcinoma?Papillary Microcarcinoma?

1. Potentially metastasizing

2. Metastatic focus of papillary carcinoma

3. Clinically insignificant

retret/PTC in /PTC in Multifocal Papillary CarcinomaMultifocal Papillary Carcinoma

• ret/PTC expression is highly prevalent in multifocal micropapillary thyroid cancer

• Identical ret/PTC rearrangements are found in 32% of patients» possible spread of a single tumor

• Discordant ret/PTC patterns in 68%» discrete primary tumors

Sugg et al, J Clin Endocrinol Metab 83:4116-4122, 1998

• Identical data using X-chromosome inactivationShattuck et al, N Engl J Med. 2005 Jun 9;352(23):2406-12

Implications of Implications of retret/PTC Data in /PTC Data in Multifocal Papillary CarcinomaMultifocal Papillary Carcinoma

• One major rationale for completion thyroidectomy in patients with “low risk”papillary carcinoma is unjustified

Fink et al, Modern Pathol 1996; 9: 816-820

HHüürthle Cell Tumorsrthle Cell Tumors

• Hürthle cell adenoma, Hürthle cell carcinoma» distinguished by

invasive behavior» controversial because of

unpredictable behavior

• Hürthle cell PTC» defined by papillary

architecture

Molecular Basis of HMolecular Basis of Hüürthle Cell rthle Cell Papillary CarcinomaPapillary Carcinoma

• ret/PTC identifies Hürthle cell tumors with lymph node mets» allows distinction from Hürthle cell adenoma» better prognosis than Hürthle cell carcinoma

Cheung et al, J Clin Endocrinol Metab 85: 878-882, 2000

mtDNAmtDNA, GRIM19, GRIM19• Altered ATP synthesis

Savagner et al, JCEM 2001;86:4920–4925

• mtDNA somatic eventsBonore et al, Cancer Res 2006; 66:6087–6096 Gasparre et al, PNAS 2007: 104, 9001–9006

• Mutations in non-neoplastic and neoplastic oncocytic cells » Not specific to neoplastic transformation » Associated with BRAF, ret/PTC etc

• GRIM19 (19p13.2) somatic and germline eventsMaximo et al, Virchows Arch 2000 Sobrinho-Simoes et al, Int J Surg Pathol 2005


Molecular Diagnosis in Thyroid Molecular Diagnosis in Thyroid AspiratesAspirates-- Papillary CarcinomaPapillary Carcinoma

• ret/PTCCheung et al, J Clin Endocrinol Metab 2001

• BRAFSalvatore et al, J Clin Endocrinol Metab 2004

Improved diagnosis with combined morphology and molecular testing

After “The Anatomy Lecture of Dr. Nicolaes Tulp” – Rembrandt, 1632(Courtesy of Dr. Carlos Cordón, New York, USA)

BRAF Kinase Inhibition Arrests BRAF Kinase Inhibition Arrests Thyroid Cancer Growth In VivoThyroid Cancer Growth In Vivo

Salvatore G et al, Clin Cancer Res 2006;12:1623-9

However ………

Clinical trials have failed to show

effectiveness of BRAF inhibitors


ThyroidFollicular

Cell

FollicularAdenoma


FollicularCarcinoma

PapillaryCarcinoma

Tall Cell Papillary

Carcinoma

Insular Carcinoma

GsTSH-R

BRAFRET/PTCTRK

p53

β-cateninPIK3CA

PPARγ

???????

MetastaticPapillary

Carcinoma

HyperplasiaAnaplasticCarcinoma

β-cateninPIK3CARas

Epigenetic Control: DNA MethylationEpigenetic Control: DNA Methylation

N Engl J Med. 2007 Feb 15;356(7):731-3


ThyroidFollicular

Cell

FollicularAdenoma


FollicularCarcinoma

PapillaryCarcinoma

Tall Cell Papillary

Carcinoma

Insular Carcinoma

GsTSH-R

RET/PTCBRAFTRK

p53

rasβ-catenin

PPARγ

EpigeneticDysregulation

MetastaticPapillary

Carcinoma

Hyperplasia

rasβ-catenin

AnaplasticCarcinoma


Cyclin D1 and p27 Predict Metastasis Cyclin D1 and p27 Predict Metastasis in Papillary Carcinomain Papillary Carcinoma

Khoo et al, J Clin Endocrinol Metab 2002, 87:1814-8

Vitamin D Targets p27 Degradation Vitamin D Targets p27 Degradation in Thyroid Cancerin Thyroid Cancer• VD/EB1089 induce intranuclear p27 accumulation by

diminished degradation• VD/EB1089 hypophosphorylate p27 in a phosphatase

dependent process that involves the Akt pathway but may be PTEN independent

Liu et al, Am J Pathol 2002;160:511-9• In an orthotopic model, in vivo VD administration

» decreases tumor volume» increases p27 accumulation» enhances cellular differentiation» decreases lung metastases

Dackiw et al, Endocrinology 2004;145:5840-6

• CITED-1 (L)• Galectin-3• Fibronectin ( R)• HGF, MET• TPO• COX-2• CD44V6• CD57

Prasad et al: Modern Pathology 2005;18:48-57

Are There Other Targets of VD?Are There Other Targets of VD? Fibronectin is Upregulated in Fibronectin is Upregulated in Papillary Thyroid CarcinomaPapillary Thyroid Carcinoma• Increased cDNA expression in microarray studies

of papillary carcinoma cf normal• Diminished FN immunoreactivity reported at

invading edge of aggressive thyroid cancers• Negative in poorly-differentiated and anaplastic

carcinomas• Function unclear

» Increasing invasion?» Reactive upregulation?

DownDown--regulation of FN Promotes regulation of FN Promotes Tumor Growth and MetastasisTumor Growth and Metastasis

0 5 10 15 21 26Days after cancer cell injection

Tum

or v

olum

e (m

m3 )

0

500

1000

1500

2000

2500

3000

3500

4000

4500

5000 ControlsiRNA

FN siRNA

**

*

*

Control FN-siRNA

Liu et al, Mol Endo 2005; 19(9):2349-57

Mice n # of mice with mets # of lesions/mouse pControl 9 1 single FN-siRNA 9 6 multiple <0.05

Fibronectin in Thyroid CancerFibronectin in Thyroid Cancer

• Fibronectin mediates adhesion in thyroid carcinoma and restrains tumour growth

• VD upregulates fibronectin and restores adhesiveness of thyroid carcinoma

• The PTEN/PI3 Kinase pathway is involved in FN regulation and VD action on FN and adhesion

• The mechanism underlying overexpression in papillary carcinoma is unclear, but appears to be compensatory, and is lost in aggressive and dedifferentiated thyroid cancers

Liu et al, Mol Endo 2005; 19(9):2349-57


CEACAM1CEACAM1aka biliary glycoprotein (BGP), CD66a, Caka biliary glycoprotein (BGP), CD66a, C--CAM1 and pp120CAM1 and pp120

• A member of the CEA family (Ig superfamily)• A putative TSG

» Down-regulated in colon, prostate, liver, endometrial, bladder and breast cancer

» Reduces proliferation in human prostate cancer cell lines in vitro and in vivo

• Also implicated as an oncogene» Over-expressed in gastric cancer, non-small cell lung cancer and

malignant melanomas» Facilitates metastatic tumor spread» Shows angiogenic function as a major target of VEGF

CEACAM1 Expression Predicts Metastasis in PTC

• CEACAM1 is expressed in a small PTCswith lymph node spread

• CEACAM1 has a novel dual role in thyroid carcinoma: it has a suppressive effect on thyroid cell proliferation and increases adhesion, while promoting invasion and metastasis

Liu et al, Oncogene 2007; 26:2747-58

CEACAM1 in Thyroid CancerCEACAM1 in Thyroid Cancer• CEACAM1 is expressed in a small thyroid malignancies

with lymph node spread • CEACAM1 has a novel dual role in thyroid carcinoma:

it suppresses thyroid cell proliferation, while promoting invasion and metastasis

Liu et al, Oncogene 2007; 26:2747-58• VD inhibits CEACAM1 to promote insulin/IGF-I receptor

signaling without compromising anti-proliferative action• CEACAM1 represents a target for VD therapy which may

have potential therapeutic applicationsLiu et al, Lab Invest 2011 ;91(1):147-56

TMA Profiling Shows Divergent TMA Profiling Shows Divergent Expression of Expression of FGFRsFGFRs in the Thyroidin the Thyroid

FGFR2 is expressed exclusively in normalthyroid

FGFR1 is expressed in hyperplastic and neoplastic lesions

St Bernard et al, Endocrinology 146:1145-1153, 2005

FGFR1, PTCFGFR2, Normal thyroid

FGFR2FGFR2--IIIb Interrupts Signaling IIIb Interrupts Signaling Upstream of BRAF/MAPK Upstream of BRAF/MAPK

Kondo et al, Cancer Res 2007;67: 5461

FGFR2FGFR2--IIIb Represses MAGEIIIb Represses MAGE--A3/6A3/6

Kondo et al, Clin Cancer Res 2007;13(16):4713-20

MAGE subgroup I members , MAGE-A, B, C, are expressed in several tumors, but not in normal tissues except testis and placenta

“Cancer-testis antigens”

Dr. S. L. Asa Thyroid PathologyM

AG

E-A

3

C

ontr

ol

Time: 0 5 10 15 20 (hrs)

MAGEMAGE--A3 Promotes Migration & InvasionA3 Promotes Migration & Invasion

Liu et al, Cancer Res 2008;68:8104-8112

0%

50%

100%

150%

200%

250%

300%

Inva

sive

Cel

ls

C MAGE A3Control MAGE-A3

Tum

or v

olum

e (m

m3 )

0 5 10 15 21

0

250

500

750

1000

1250

1500

1750

2000

2250

2500Control

MAGE A3

0

0.5

1

1.5

2

2.5

Tum

or w

eigh

t (gr

am)

*

*

* *

N=20 N=20

MAGEMAGE--A3 Enhances Tumor Growth A3 Enhances Tumor Growth

Control MAGE-A3

00.5

11.5

22.5

33.5

44.5

55.5

6

Tum

or w

eigh

t (gr

am)

N=20 N=17

*

Days after injection

0

500

1000

1500

2000

2500

3000

3500

4000

4500

5000

5500

6000

6500Control

MAGE

Tum

or v

olum

e (m

m3 )

*

*

**

0 5 10 15 21 25

Control MAGE-A3

MAGEMAGE--A3 Promotes Metastasis A3 Promotes Metastasis

Control

MAGE-A3

Day 15 Day 20 Day 25


MAGE in Thyroid CancerMAGE in Thyroid Cancer• Downregulation or FN or FGFR2 increase tumor

growth and metastasis• Downregulation of FN or FGFR2 induce expression of

MAGE-A3 through histone methylation• MAGE- A3 mediates p21 down-regulation,

accelerated cell cycle progression, increased cell migration rate, invasion and metastasis

• MAGE-A3 is a functional integrator of diverse signals in mediating cancer progression


MAGE

• Normal thyroid tissue exhibits weak cytoplasmic and strong nuclear MAGE reactivity.

• Tumors exhibit an increase in cytoplasmic MAGE scores that correlates with clinical behavior» larger tumors have higher MAGE scores» correlation between MAGE cytoplasmic score and

number of lymph node metastases

Cheng et al, Endocrine Related Cancer 2009;16:455-466

Proteomic Biomarkers in PTC• 410 PTCs with morphologic and clinical data• BRAF status known• TMA analysis of:

• Histopathologic biomarkers of malignancy: Galectin-3, CK 19, HBME-1

• Cell differentiation factors: NIS, CITED-1 • Nuclear receptors: ERα, ERβ, and PPAR-γ• Adhesion molecules: CEACAM-1, Osteopontin,

Fibronectin, E-Cadherin• Cell cycle regulators: Cyclin-D1, p53, p27, p21


BRAF Mutations & OutcomeBRAF Mutations & Outcome

Cheng et al, Clin Cancer Res 2011:17(8):2385-94

410 PTCs

ETE: ↑membranous CK19, HBME, Gal 3,OPN↓cytoplasmic HBME , CK19 ↑ nuclear ERβ, Gal3, p53

LNM:↑ membranous HBME1, CK19, Gal3↓ cytoplasmic FBN and CK19 ↑ nuclear Gal3, Erβ

VI:↑ membranous Gal3 ↓ cytoplasmic Gal3

PTC PTC ProteomeProteome

Cheng et al, Clin Cancer Res 2011:17(8):2385-94

ProteomeProteome of of Invasive PTCInvasive PTC

Cheng et al, Clin Cancer Res 2011 in press

ETE: ↑membranous CK19, HBME, Gal 3,OPN↓cytoplasmic HBME , CK19 ↑ nuclear ERβ, Gal3, p53

LNM:↑ membranous HBME1, CK19, Gal3↓ cytoplasmic FBN and CK19 ↑ nuclear Gal3, Erβ

VI:↑ membranous Gal3 ↓ cytoplasmic Gal3

PTC PTC ProteomeProteomeBy MorphologyBy MorphologyFVPTC:

ETE: ↑ membranous CK19, HBME, Gal3, OPN↓cytoplasmic CK19↑nuclear Gal3

LNM:↑membranous HBME1, CK19 and Gal3↓membranous E-Cadherin↓cytoplasmic HBME1, CK19, FBN↑ nuclear Gal3 ↓nuclear PPARγ

VI:↓ nuclear PPARγ

Classic PTC

ETE: ↑ ERβLNM: ↑cyclin D1, ↓FBNVI: ↓ p27

• The diagnosis of thyroid cancer is evolving as

molecular data clarify the significance of

morphologic features and behaviors

• Our data predict the need for targeting

epigenetic factors along with intragenic mutations

in the control of thyroid cancer progression.

ConclusionsConclusions Thanks ToThanks To…………..

♥ Shereen Ezzat

• Robyn Apel• Lei Zheng• Sonia Sugg• Mark Khoo• Carol Cheung• Wei Liu• P. Huang• Rosanne St. Bernard• Catherine Wei• Daniel Winer• Tetsuo Kondo• Xuegong Zhu• Sonia Cheng

• Alan Dackiw• Lorne Rotstein• Ana-Maria Bamberger• Christoph Bamberger• Christoph Wagener

Cancers on the Rise: Changing Concepts Trends in … Concepts Thyroid Pathology Sylvia L. Asa, M.D.,...

Documents

Transcript of Cancers on the Rise: Changing Concepts Trends in … Concepts Thyroid Pathology Sylvia L. Asa, M.D.,...